PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
|Articles|October 3, 2013
B. Braun OEM Division - System-built Solutions.
If you need a trusted outsourcing partner for pharmaceutical contract manufacturing and customized medical devices, turn to B. Braun OEM - one of the world’s leading healthcare companies
Advertisement
B. Braun OEM Division – System-built Solutions.
Expertise in contract manufacturing and infusion therapy products
B. Braun supplies healthcare markets worldwide and is employing approx. 48,000 individuals. Based on this expertise the B. Braun OEM Division serves the pharmaceutical and medical devices industry.
At B. Braun OEM we offer contract manufacturing for infusion, irrigation and volume replacement solutions as well as standard injectables, anesthetics and dermatological products like creams, gels and pomades. Depending on the product requirements, we can fill in containers of different sizes, shapes and materials.
Furthermore, we provide a wide range of infusion therapy products. We supply all that is needed to admixture and infuse or inject a drug. You can order standard products or a customized version.
Partnering with us provides you with complete outsourcing knowledge. Our project management teams are the experts for individual customer ideas.
We can handle manufacturing projects and will customize a product or set according to your detailed specifications.
Products:
- Pharmaceutical Solutions
- Medical Devices
- Products for Disinfection and Hygiene
Project management services:
- Customized Products (modified characteristics, private label etc.)
- Customized Sets Pharmaceutical
- Contract Manufacturing
- Common Development
B. Braun Melsungen AG
Website:
E-mail: [email protected]
Advertisement
Related to this article
The recently opened NJ spray drying facility doubles capacity for amorphous solid dispersions, addressing solubility limits in roughly 70% of small-molecule pipelines.
Lori Dingledine, QC Director Microbiological Control and GTIC Operations at Genentech, provided input on the regulations surrounding raw material manufacturing and use for ATMPs in a presentation at the 2026 PDA/FDA Joint Regulatory Conference.
FDA opens applications for its Expedited IND Pilot, pairing sponsors with qualified research institutions to test rolling CMC review ahead of first-in-human trials.
2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
Karthik Iyer, Eli Lilly, details an AI system linking GMP findings, audits, and deviations for cited, inspection-ready regulatory intelligence.
At the PDA/FDA Joint Regulatory Conference 2026, Helen Motamen, MS
global head, Sanofi Quality Audit, Inspection, Intelligence & Advocacy, at Sanofi, provided advice for creating a strong internal audit program.
At PDA/FDA Joint Regulatory Conference 2026, PCI Pharma's Bassler details how a QMS overhaul turned an FDA 483 into stronger quality culture.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Driving Quality Culture to Manage Risk: Lessons from an FDA Inspection Response
2
FDA's IND Pilot Puts CMC Review First
3
Mature Medicines Divestment Signals Shift in Manufacturing Strategy
4
Spray Drying Capacity Signals Faster Paths for Poorly Soluble Drugs
5